Caplin Point Laboratories Ltd (CAPLIPOINT) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 18814.41 Cr. Figures below are as reported and are shown with their source and date.
Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu and currently employs 777 full-time employees. The firm is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. The company has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
Source: finedge · as of 2026-09-29
Last close (₹): 2,249.1
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 2,187.19 | 641.24 | 84.36 |
| Mar 2025 | 1,937.47 | 536.31 | 70.56 |
| Mar 2024 | 1,694.1 | 457.08 | 60.19 |
| Mar 2023 | 1,466.73 | 376.26 | 49.57 |
| Mar 2022 | 1,269.41 | 308.45 | 40.7 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.